CYP3A4*22 may increase bleeding risk in ticagrelor users

Basic Clin Pharmacol Toxicol. 2023 Aug;133(2):202-207. doi: 10.1111/bcpt.13884. Epub 2023 May 31.
No abstract available

Keywords: adverse drug events; antiplatelet drugs; ischemic heart disease; pharmacogenetics; polymorphism; precision medicine.

MeSH terms

  • Acute Coronary Syndrome*
  • Cytochrome P-450 CYP3A
  • Hemorrhage / chemically induced
  • Humans
  • Percutaneous Coronary Intervention*
  • Platelet Aggregation Inhibitors / adverse effects
  • Ticagrelor / adverse effects
  • Treatment Outcome

Substances

  • Ticagrelor
  • Cytochrome P-450 CYP3A
  • Platelet Aggregation Inhibitors
  • CYP3A4 protein, human